Mounjaro and Zepbound have helped boost the company's market cap. New data indicate these drugs do more than just help patients lose weight, contributing to potentially lowering risks to hearts and ...

Eli Lilly & Co., the maker of the blockbuster Mounjaro diabetes drug, plans to invest more than $1 billion for contract manufacturing in India, amid 100% US tariff on the pharma sector. Eli Lilly, ...

Eli Lilly has committed to setting a new standard for on-screen representation of common chronic diseases, and it walked the walk with its recent sponsorship of a segment on “Project Runway.” In the ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ...

Oct 6 (Reuters) - Eli Lilly (LLY.N), opens new tab will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, ...

American pharmaceutical giant Eli Lilly and Company is investing over $1 billion (approx Rs 8,900 crore) in India to establish new contract manufacturing facilities, including a significant hub in ...

Oct 8 (Reuters) - Telehealth company HealthTap said on Wednesday it is joining Eli Lilly's (LLY.N), opens new tab digital healthcare platform, LillyDirect, to offer virtual diabetes management ...

Eli Lilly and Company on Monday (October 6, 2025) said it will invest more than $1 billion over the next several years into new contract manufacturing, as well as establish in Hyderabad a new facility ...

This article first appeared on GuruFocus. Eli Lilly and Co. (NYSE:LLY) is making a bold long-term bet on India. The U.S. drugmaker plans to pour more than $1 billion into expanding its contract ...

Amid Eli Lilly's efforts to strengthen its global manufacturing network, the Indianapolis pharma giant is splashing more than $1 billion into its Indian operations, with plans to tap local partners ...

"Lilly is actively engaging with contract manufacturers in India," the company told Reuters, but did not divulge any further details. Lilly's investment plans in India come at a time when global ...

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — Peter Marks, the ...